71,739 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Bought by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D purchased a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 71,739 shares of the company’s stock, valued at approximately $1,965,000. State of New Jersey Common Pension Fund D owned approximately 0.08% of Myriad Genetics at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its holdings in shares of Myriad Genetics by 90.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,805 shares of the company’s stock valued at $188,000 after buying an additional 4,193 shares during the last quarter. Swiss National Bank raised its holdings in shares of Myriad Genetics by 8.2% in the 1st quarter. Swiss National Bank now owns 174,700 shares of the company’s stock valued at $3,725,000 after purchasing an additional 13,300 shares during the period. ProShare Advisors LLC raised its holdings in shares of Myriad Genetics by 14.2% in the 1st quarter. ProShare Advisors LLC now owns 23,993 shares of the company’s stock valued at $512,000 after purchasing an additional 2,990 shares during the period. State Board of Administration of Florida Retirement System raised its holdings in shares of Myriad Genetics by 8.9% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 25,107 shares of the company’s stock valued at $583,000 after purchasing an additional 2,050 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Myriad Genetics by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 10,035,708 shares of the company’s stock valued at $213,961,000 after purchasing an additional 81,475 shares during the period. 99.02% of the stock is currently owned by institutional investors and hedge funds.

Myriad Genetics Stock Performance

Shares of MYGN stock opened at $15.25 on Monday. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -11.73 and a beta of 1.93. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. Myriad Genetics, Inc. has a 52 week low of $15.18 and a 52 week high of $29.30. The firm’s 50-day simple moving average is $23.43 and its two-hundred day simple moving average is $24.67.

Insider Activity

In related news, Director Colleen F. Reitan sold 46,012 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the completion of the transaction, the director now owns 42,533 shares of the company’s stock, valued at approximately $1,188,797.35. The trade was a 51.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Paul J. Diaz sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $22.93, for a total transaction of $343,950.00. Following the transaction, the chief executive officer now directly owns 962,378 shares of the company’s stock, valued at approximately $22,067,327.54. This represents a 1.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,012 shares of company stock valued at $1,900,485 over the last quarter. Company insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on MYGN shares. Scotiabank upped their target price on shares of Myriad Genetics from $29.00 to $34.00 and gave the company a “sector outperform” rating in a report on Tuesday, August 13th. JPMorgan Chase & Co. upped their target price on shares of Myriad Genetics from $17.00 to $20.00 and gave the company an “underweight” rating in a report on Wednesday, August 7th. Wells Fargo & Company started coverage on shares of Myriad Genetics in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $35.00 price target on the stock. TD Cowen increased their target price on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Finally, Piper Sandler decreased their target price on shares of Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating on the stock in a research report on Monday, November 11th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Myriad Genetics presently has a consensus rating of “Hold” and a consensus target price of $28.36.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.